Intravacc designs and develops vaccines, improves the production processes of vaccines, and produces drug substances and products at cGMP-level to enable pre-clinical and clinical studies. Our leading principle is the Vaccine Development Pathway (VDP), which was fully implemented in 2020.
Established blueprints and scalable processes
For the development of new vaccines, Intravacc uses established blueprints and scalable platform production processes. These are designed according to the regulatory requirements, using mathematical models, and are scalable from lab to high-volume production-scale bioreactors. Rationally designed processes and their products are tested in our state-of-the-art laboratory facilities using the latest ICH-guidelines and insights.
Intravacc focusses on the development of a proper formulation suitable for the intended administration route of a new vaccine, that is also stable upon storage. The stability of new formulations is tested in accelerated, real-time and in-use stability studies using the appropriate set of assays.
Water-free vaccine products
However, some vaccines are difficult to stabilize in a liquid formulation, especially if these vaccines contain live-attenuated viruses. To solve this, Intravacc has the facilities and expertise to develop water-free vaccine products (e.g. by lyophilization or spray-drying). Drying techniques are also applied for the preparation of stable seed lots and reference materials.